טוען...
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
BACKGROUND. PD-L1 expression and tumor mutational burden (TMB) have emerged as important biomarkers of response to immune checkpoint inhibitor (ICI) therapy. These biomarkers have each succeeded and failed in predicting responders for different cancer types. We sought to describe the PD-L1 expressio...
שמור ב:
| הוצא לאור ב: | JCI Insight |
|---|---|
| Main Authors: | , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society for Clinical Investigation
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6482991/ https://ncbi.nlm.nih.gov/pubmed/30895946 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.126908 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|